Literature DB >> 7273265

Structure-pharmacokinetic relationships for misonidazole analogues in mice.

P Workman, J M Brown.   

Abstract

We have compared the mouse pharmacokinetics of six analogues of the hypoxic cell sensitizer misonidazole (MISO). The analogues were all uncharged and similar in redox potential, but widely different in octanol-water partition coefficient (range 0.026-1.5). Lipophilic analogues were cleared mainly by metabolism and non-linear elimination kinetics were seen at high doses. Hydrophilic analogues, including desmethylmisonidazole, SR-2508, and SR-2555, were removed principally by renal clearance exhibiting linear elimination kinetics. Lipophilic analogues were cleared more rapidly after hepatic microsomal enzyme induction by phenobarbitone, whereas the kinetics of hydrophilic analogues were unaffected. Low-dose clearance was similar for most of the analogues. But the hydrophilic SR-2555 was cleared twice as quickly as MISO, and the lipophilic Ro 07-0913 seven times faster than MISO. Plasma protein binding was low for all the analogues. The significance of these results for the predictive value of the mouse as a model for man is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7273265     DOI: 10.1007/BF00253009

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  29 in total

1.  Misonidazole-a drug for trial in radiotherapy and oncology.

Authors:  S Dische; M I Saunders; I R Flockhart; M E Lee; P Anderson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-06       Impact factor: 7.038

2.  Peripheral neuropathy related to misonidazole: incidence and pathology.

Authors:  R C Urtasun; J D Chapman; M L Feldstein; R P Band; H R Rabin; A F Wilson; B Marynowski; E Starreveld; T Shnitka
Journal:  Br J Cancer Suppl       Date:  1978-06

3.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

4.  SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use.

Authors:  J M Brown; N Y Yu; D M Brown; W W Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-06       Impact factor: 7.038

5.  The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.

Authors:  R A White; P Workman; J M Brown
Journal:  Radiat Res       Date:  1980-12       Impact factor: 2.841

6.  Single-dose pharmacokinetics of the trypanosomicide benznidazole in man.

Authors:  J Raaflaub; W H Ziegler
Journal:  Arzneimittelforschung       Date:  1979

7.  In vivo evaluation of the radiosensitizing and cytotoxic properties of newly synthesized electron-affinic drugs.

Authors:  J M Brown; N Y Yu; M J Cory; R B Bicknell; D L Taylor
Journal:  Br J Cancer Suppl       Date:  1978-06

8.  Effect of lipophilicity of nitroimidazoles on radiosensitization of hypoxic bacterial cells in vitro.

Authors:  R F Anderson; K B Patel
Journal:  Br J Cancer       Date:  1979-06       Impact factor: 7.640

9.  A drug for improved radiosensitization in radiotherapy.

Authors:  S Dische; J F Fowler; M I Saunders; M R Stratford; P Anderson; A I Minchinton; M E Lee
Journal:  Br J Cancer       Date:  1980-07       Impact factor: 7.640

10.  Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.

Authors:  P Workman
Journal:  Br J Cancer       Date:  1979-09       Impact factor: 7.640

View more
  20 in total

Review 1.  Magnetic resonance spectroscopy and imaging methods for measuring tumour and tissue oxygenation.

Authors:  C L McCoy; D J McIntyre; S P Robinson; E O Aboagye; J R Griffiths
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.

Authors:  Nicolas Christian; Anne Bol; Marc De Bast; Daniel Labar; John Lee; Pierre Mahy; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-03       Impact factor: 9.236

Review 3.  Functionalized Nitroimidazole Scaffold Construction and Their Pharmaceutical Applications: A 1950-2021 Comprehensive Overview.

Authors:  Ria Gupta; Sumit Sharma; Rohit Singh; Ram A Vishwakarma; Serge Mignani; Parvinder Pal Singh
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-30

4.  Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.

Authors:  M I Walton; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  CB 1954 revisited. I. Disposition kinetics and metabolism.

Authors:  P Workman; R A White; K Talbot
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 6.  Nitroimidazoles and imaging hypoxia.

Authors:  A Nunn; K Linder; H W Strauss
Journal:  Eur J Nucl Med       Date:  1995-03

Review 7.  Development of quantitative structure-pharmacokinetic relationships.

Authors:  J M Mayer; H van de Waterbeemd
Journal:  Environ Health Perspect       Date:  1985-09       Impact factor: 9.031

8.  Effects of localised tumour hyperthermia on pimonidazole (Ro 03-8799) pharmacokinetics in mice.

Authors:  M I Walton; N M Bleehen; P Workman
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

9.  A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy.

Authors:  C P Lee; G S Payne; A Oregioni; R Ruddle; S Tan; F I Raynaud; D Eaton; M J Campbell; K Cross; G Halbert; M Tracy; J McNamara; B Seddon; M O Leach; P Workman; I Judson
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

10.  Sensitization of normal and malignant tissue to cyclophosphamide by nitroimidazoles with different partition coefficients.

Authors:  D G Hirst; J L Hazlehurst; J M Brown
Journal:  Br J Cancer       Date:  1984-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.